JNJ might conduct bigger study to get the combo added to label, GILD certainly won't.
Agreed. Same as GILD acted with sofosbuvir/daclatasvir combo. I know many patients and docs would want to use this combo the minute it hits the market, but again I think that most will have to wait until late 2014-early 2015 for an on label all oral DAA regimen.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.